HBC Hofseth Biocare

Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2023

Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2023

The Annual General Meeting of Hofseth BioCare ASA will be held at the company's premises at Kipervikgata 13, 6003 Ålesund, on 28 April 2023 at 13:00 CET.

The notice of the Annual General Meeting was sent to the shareholders on 5 April 2023, and unfortunately this stock exchange notice was not sent concurrently. Please find the notice to the Annual General Meeting attached.

For further information, please contact:

Jon Olav Ødegård, CEO of Hofseth BioCare ASA

Phone:

E-mail:

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act

Attachment



EN
13/04/2023

Underlying

HBCHofseth Biocare

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: USD 5 Million Divestment in Aecorbio

Hofseth Biocare ASA: USD 5 Million Divestment in Aecorbio NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. (Ålesund, 24 October 2025) Reference is made to the stock exchange notices published by Hofseth BioCare ASA ("HBC" or the "Company") earlier today regarding the launch of a private placement in the amount of between ...

1h / 34m 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: Contemplated Private Placement and Partial Divest...

Hofseth BioCare ASA: Contemplated Private Placement and Partial Divestment of Shares in Aecorbio NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Hofseth BioCare ASA ("HBC" or the "Company") today announces a contemplated private placement (the "Private Placement") of between 86,096,132 and 100,638,889 new shares ("Offer ...

1h / 42m 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUAT...

Hofseth Biocare ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUATION FOR ONGOING FT-002A PEPTIDE DEVELOPMENT IN PROSTATE CANCER AecorBio Inc., formerly known as HBC Immunology Inc, has successfully completed a further equity financing round of $1.5m from existing and new investors at a company valuation of $30 million. This funding will enable AecorBio to complete the investigational work of its lead peptide candidate FT-002a, in advanced prostate cancer, to enable an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in 2026. Filing the IND wil...

September 17, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: ProGo, the world’s first consumer health GLP-1 & ...

Hofseth Biocare ASA: ProGo, the world’s first consumer health GLP-1 & GIP receptor agonist with muscle mass protection via inhibition of Myostatin and Activin A pathways HBC has today released a whitepaper demonstrating how its bioactive peptide ingredient ProGo® uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs to be protected to optimize the benefits of weight loss and support a healthy metabolism. ProGo®️ addresses these needs through its unique triple action properties: highly absorbable protein with a complete amino acid profi...

September 9, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science...

Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science Asia, Oceania, Middle East and Africa Region, Paul Bruhn HBC is delighted to announce the appointment of Paul Bruhn as Head of New Business Development. Mr Bruhn has over 25 years’ experience in healthcare and the medical nutrition space spanning Novartis Medical Nutrition and Nestle Health Science. He has been leading businesses across multiple geographies including Japan, Korea, India, Middle East, Singapore, Canada, Switzerland and Australia and hence has an excellent overlap with corporates focused on developing the...

September 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch